Tempo Therapeutics has received a $2.25 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to advance its MAP™ technology platform for complex wound healing.

The award positions Tempo Therapeutics within a growing field of regenerative wound-care companies competing to address a clinical problem that dermatologists and wound-care specialists confront daily: wounds that fail to close with standard of care. Complex wounds — including chronic, hard-to-heal, and structurally compromised defects — remain among the most resource-intensive conditions managed in dermatology and vascular practices, and the NIH's decision to fund MAP™ development signals institutional interest in tissue-engineered approaches to the problem.

What the grant funds

The $2.25 million SBIR award will support continued development of the MAP™ platform. SBIR grants are competitive, peer-reviewed federal awards made through the NIH to small biomedical companies, and Phase II-level funding at this scale typically backs translational work — advancing a technology from preclinical validation toward clinical readiness. The NIH does not award these grants on manufacturer claims alone; applicants must present reviewed scientific data supporting the technology's feasibility and potential clinical value.

The company frames MAP™ as a technology designed for complex wound healing. According to the announcement, the platform is intended to support tissue repair in wounds where conventional dressings, debridement, and offloading prove insufficient. Details on the specific mechanism, trial endpoints, or regulatory timeline were not disclosed in the announcement, and Tempo Therapeutics has not yet published paired clinical data with the funding notice.

Why the funding matters for dermatology

For clinicians, the relevant question with any wound-healing platform is whether it can accelerate closure, reduce infection risk, and improve outcomes in cohorts that standard protocols fail. Complex wounds — diabetic foot ulcers, venous leg ulcers, pressure injuries, and surgical or traumatic defects — impose substantial morbidity, and the armamentarium of advanced therapies, from cellular and tissue-based products to negative-pressure wound therapy, still leaves a meaningful share of patients unhealed at 12 weeks.

A peer-reviewed NIH SBIR award at $2.25 million gives Tempo Therapeutics the capital to push MAP™ through the next stage of that evidence-building process. Whether the platform can demonstrate measurable healing outcomes in controlled studies will determine its eventual place in the wound-care pathway — and whether dermatologists managing refractory wounds gain a genuinely new option rather than an incremental one.

Next steps

The grant funds advancement of the technology toward clinical application. Investigators and wound-care clinicians will watch for Tempo Therapeutics to translate this federal investment into disclosed study designs, defined healing endpoints, and eventual human data. The award's forward trajectory now depends on the company delivering results that survive peer review and, ultimately, regulatory scrutiny.